

# Peter Chatfield

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4667236/publications.pdf>

Version: 2024-02-01

5  
papers

46  
citations

2682572

2  
h-index

2053705

5  
g-index

5  
all docs

5  
docs citations

5  
times ranked

176  
citing authors

#	ARTICLE	IF	CITATIONS
1	Fracture Risk in Men with Metastatic Prostate Cancer Treated With Radium-223. <i>Clinical Genitourinary Cancer</i> , 2021, 19, e299-e305.	1.9	6
2	Abiraterone in patients with recurrent epithelial ovarian cancer: principal results of the phase II Cancer of the Ovary Abiraterone (CORAL) trial (CRUK A16037). <i>Therapeutic Advances in Medical Oncology</i> , 2020, 12, 175883592097535.	3.2	2
3	TOPARP-B: A phase II randomized trial of the poly(ADP)-ribose polymerase (PARP) inhibitor olaparib for metastatic castration resistant prostate cancers (mCRPC) with DNA damage repair (DDR) alterations.. <i>Journal of Clinical Oncology</i> , 2019, 37, 5005-5005.	1.6	35
4	Fracture risk after radium-223 (Ra-223) in metastatic castration resistant prostate cancer (mCRPC).. <i>Journal of Clinical Oncology</i> , 2019, 37, e16513-e16513.	1.6	1
5	Radium-223: Disease response and fracture assessment by whole body diffusion-weighted MRI (WB-DWMRI) in metastatic castration resistant prostate cancer (mCRPC).. <i>Journal of Clinical Oncology</i> , 2018, 36, 5024-5024.	1.6	2